Court Denies Renovaro Motion for an Expedited Trial in July
Provided By GlobeNewswire
Last update: May 27, 2025
PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc.
Read more at globenewswire.com
